Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986463 in Advanced Malignant Tumors
NCT06476808Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2024
- Primary completion
- Dec 2028
- Countries
- 5
01
Overview
Phase 1, open-label trial of BMS-986463 in high grade serous ovarian carcinoma (HGSC), uterine serous carcinoma (USC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events at 108 weeks, Serious Adverse Events at 108 weeks and 3 more. Started Sep 2024; status: recruiting.
02
Drugs
BMS-986463
03
Conditions
high grade serous ovarian carcinoma (HGSC)uterine serous carcinoma (USC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06476808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06476808.